Management of LSIL with High‑Risk HPV in Women Aged 30–65 Years

Referral Indications

• Women with LSIL who test positive for high‑risk HPV have an immediate risk of CIN 2+ of approximately 16–19 %, which exceeds the NCCN‑recommended colposcopy referral threshold of 8–10 %【1】【2】.
• The combination of LSIL cytology and a positive high‑risk HPV result is managed in the same way as HPV‑positive ASC‑US in women ≥ 30 years, according to NCCN guidelines【3】【4】.
• At age 37 the patient falls within the 30‑65 year age group for which cotesting (cytology + HPV) is standard; the conservative observation strategies used for women 21‑24 years do not apply【5】【6】.

Colposcopy Procedure

• The entire transformation zone should be visualized with 10‑16× magnification after application of a 3‑5 % acetic acid solution, as recommended by the NCCN【3】【7】.
• Directed biopsies must be taken from any acetowhite lesions or areas with abnormal vascular patterns to exclude invasive disease and to stage pre‑invasive disease【3】【4】.
• Endocervical curettage is not required when the squamocolumnar junction is fully visualized (adequate examination)【5】【3】.

Management Based on Histology

CIN 1

• CIN 1 should not be treated immediately; treatment is reserved for lesions persisting ≥ 2 years, per NCCN guidance【5】【6】.
• Follow‑up includes HPV testing at 12 months or repeat cytology at 6 and 12 months (American Family Physician)【8】.
• Return to colposcopy if HPV remains positive or cytology shows ASC‑US or a higher grade (American Family Physician)【8】.

CIN 2

• Treatment is generally recommended for women > 25 years; observation is limited to the 21‑24 year age group (NCCN)【5】【6】.
• Accepted treatment modalities include LEEP, cold‑knife conization, or ablative procedures such as laser ablation or cryotherapy (NCCN)【5】【3】.

CIN 3

• Immediate treatment with a diagnostic excisional procedure (e.g., LEEP or cold‑knife conization) is mandatory (NCCN)【5】【6】.
• Hysterectomy is not the primary treatment option for CIN 3 (NCCN)【5】【6】.

Negative Colposcopy (No CIN)

• Repeat cotesting (cytology + HPV) at 12 months is recommended (American Family Physician)【8】.
• If both tests remain negative, the patient returns to routine screening (American Family Physician)【8】.
• If either test is abnormal, repeat colposcopy is indicated (American Family Physician)【8】.

Pitfalls to Avoid

• Do not defer colposcopy in favor of repeat cytology alone in the 30‑65 year algorithm; this differs from the conservative approach used for women 21‑24 years (NCCN)【5】【3】【6】.
• Do not employ a “see‑and‑treat” strategy for LSIL, even when HPV‑positive; this approach is reserved for HSIL in adult women (American Family Physician)【8】.
• Do not treat CIN 1 immediately, as overtreatment can cause unnecessary cervical trauma and increase pregnancy complications (NCCN)【5】【6】.
• Do not alter screening or management based on HPV vaccination status; vaccinated and unvaccinated women follow the same protocols (NCCN)【3】【7】.

Management of LSIL with Positive High‑Risk HPV in Women ≥ 30 Years

Indications for Immediate Colposcopy

• Women aged 30–65 years with LSIL cytology and a positive high‑risk HPV test have an immediate CIN 2+ risk of ≈ 16–19 %, exceeding the 8–10 % referral threshold, therefore colposcopy is required. 9

HPV Testing and Triage

• HPV triage is not recommended for LSIL because about 71 % of LSIL cases are HPV‑positive, rendering the test insufficiently discriminatory. 10
• HPV testing should not be used to decide initial management of LSIL; the high prevalence of positivity limits its utility. 10

Colposcopic Examination Requirements

• When colposcopy is performed, endocervical assessment (curettage or sampling) is preferred if the examination is unsatisfactory or the squamocolumnar junction cannot be fully visualized. 10

Management After Histologic Diagnosis

CIN 1

• Conservative observation is advised; treatment is reserved only for lesions that persist for ≥ 2 years. 11
• Preferred follow‑up: HPV testing at 12 months; an acceptable alternative is repeat cytology at 6 and 12 months. 10
• If HPV remains positive at 12 months or cytology shows ASC‑US or higher, the patient should be re‑referred to colposcopy. 10

CIN 2 (women > 25 years)

• Treatment is recommended for CIN 2 in women older than 25 years. Acceptable modalities include LEEP, cold‑knife conization, laser ablation, or cryotherapy. 11

Negative Colposcopy (No CIN Identified)

• Perform repeat cotesting (cytology + HPV) at 12 months. 10
• If both tests are negative, return to routine screening; if either remains abnormal, repeat colposcopy is indicated. 10

Procedural Pitfalls to Avoid

• Do not defer colposcopy in favor of repeat cytology alone for women 30–65 years with LSIL and positive HPV; immediate colposcopy is required. 9
• Do not use a “see‑and‑treat” approach (immediate excision without prior biopsy) for LSIL, even when HPV‑positive; this strategy is reserved for HSIL in adult women. 10
• Do not treat CIN 1 immediately; overtreatment can cause unnecessary cervical trauma and increase the risk of preterm delivery in future pregnancies. 11